Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.59 |
| ▸ | HTR3B | O95264 | 2/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063215 | 1.00 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL165828 | 1.00 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15854567 | 1.00 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL257186 | 1.00 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15063225 | 1.00 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL25557719 | 0.89 | HTR4 (0.68) | HTR4KCNH2 | |
| SCHEMBL534970 | 0.85 | HTR4 (0.68) | HTR3ACYP2D6CYP2C9HTR4KCNH2 | |
| SCHEMBL7389242 | 0.79 | HTR4 (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2601854 | 0.79 | HTR4 (0.66) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL7392108 | 0.78 | HTR4 (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139523-B2 | 5-HT2B receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2015-09-22 | — | — | US | disclosed |
| EP-2619180-B1 | 5-HT2B RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-08 | — | — | EP | disclosed |
| US-20140187585-A1 | 5-HT2B RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-03 | — | — | US | disclosed |
| US-8703958-B2 | 5-HT2B receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-22 | — | — | US | disclosed |
| US-8703958-B2 | 5-HT2B receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-22 | — | — | US | disclosed |
| US-20130172386-A1 | 5-HT2B RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172386-A1 | 5-HT2B RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012028614-A1 | 5-HT2B RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172386-A1 | 5-HT2B RECEPTOR ANTAGONISTS | HTR2B, HTR1B, HTR3B | HTR3A 10/4885HTR3E 12/4885HTR3B 3/4885 |
| US-20140187585-A1 | 5-HT2B RECEPTOR ANTAGONISTS | HTR2B, HTR1B, HTR3B | HTR3A 10/4885HTR3E 12/4885HTR3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.